Using engineered T cells to target head and neck cancer
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
This study is testing a new treatment for head and neck cancer that uses specially modified immune cells to better find and attack cancer cells, aiming to help patients who haven't had success with other therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10455452 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy for squamous cell carcinoma of the head and neck (SCCHN) by utilizing T cells that are genetically modified to express a chimeric antigen receptor (CAR) specific to a tumor antigen. The approach aims to enhance the ability of T cells to recognize and destroy cancer cells, including those that are resistant to conventional therapies. By targeting a specific protein, CSPG4, which is found in a majority of SCCHN tumors, the therapy seeks to eliminate both differentiated cancer cells and cancer stem cells that contribute to tumor recurrence. This innovative strategy could lead to more effective treatment options for patients with this challenging type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with squamous cell carcinoma of the head and neck who have limited treatment options.
Not a fit: Patients with other types of cancers or those who do not have squamous cell carcinoma of the head and neck may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with head and neck cancer, potentially improving survival rates and reducing recurrence.
How similar studies have performed: Other research has shown promising results using CAR T cell therapies for various cancers, indicating that this approach has potential for success in treating head and neck cancer as well.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Wang, Xinhui — Massachusetts General Hospital
- Study coordinator: Wang, Xinhui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.